COVID‐19 and venous thromboembolism: A narrative review

Research and Practice in Thrombosis and Haemostasis

Rebecca L. Zon¹  Alok Khorana²  Dana E. Angelini²  Rachel P. Rosovsky³  Rushad Patell⁴  Pavania Elavalakanar⁴  Scott Kaatz⁵  Shreejith Pillai⁵  William E. Robertson⁶ 

[1] Dana Farber Cancer Institute and Massachusetts General Brigham Boston Massachusetts USA;Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Foundation Cleveland Ohio USA;Department of Medicine Massachusetts General Hospital Boston Massachusetts USA;Division of Hematology and Hematologic Malignancies Beth Israel Deaconess Medical Center Boston Massachusetts USA;Division of Hospital Medicine Henry Ford Hospital Detroit Michigan USA;National Blood Clot Alliance Department of Emergency Healthcare Dumke College of Health Professions Weber State University Ogden Utah USA;

关键词: COVID‐19;    incidence;    review;    therapeutics;    venous thromboembolism;   

DOI  :  10.1002/rth2.12666

来源: DOAJ

【 摘 要 】

Abstract COVID‐19 (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) is associated with coagulopathy through numerous mechanisms. The reported incidence of venous thromboembolism (VTE) in hospitalized patients with COVID‐19 has varied widely, and several meta‐analyses have been performed to assess the overall prevalence of VTE. The novelty of this coronavirus strain along with its unique mechanisms for microvascular and macrovascular thrombosis has led to uncertainty as to how to diagnose, prevent, and treat thrombosis in patients affected by this virus. This review discusses the epidemiology and pathophysiology of thrombosis in the setting of SARS‐CoV‐2 infection along with an updated review on the preventative and treatment strategies for VTE associated with SARS‐CoV‐2 infection.

【 授权许可】

Unknown